Description |
A cell permeable, selective inhibitor of PI 3-K&delta, (IC50= 1.82, 0.07, and 1.24 for p110β , p110&delta, , and p110γ , respectively, but may also target p110α at concentrations as high as 100 µ M with less potency) in NB-4 and primary APL cells. It has been reported that the constitutive activation of PI3K/Akt signaling in primary AML cells is predominantly attributable to PI 3-K&delta, . Pharmacologic use of PI 3-K&delta, inhibitor has been shown to block PI3K/Akt/mTOR signaling and could thereby reduce proliferation and induce apoptosis. A related study further suggests PI 3-K&delta, inhibitor as a key therapeutic target among PI 3-K isoforms for allergy- and mast cell-related diseases. |
Reference |
1. Billottet, C., et al. Cancer Res. 2009, 69, 1027
2. Ali, K., et al. J. Immunol. 2008, 180, 2538
3. Lee, K. S. et al. The FASEB Journal 2006, 20, 455. |